Financial Performance Summary

Consolidated Results (Q1 FY27)

  • Revenue from operations: ₹162.35 crore (46% YoY growth from ₹111.48 crore in Q1 FY26)
  • Total Revenue: ₹162.97 crore
  • EBITDA: ₹41 crore (13% YoY growth from ₹37 crore in Q1 FY26)
  • EBITDA Margin: 25.3% (up from 21.9% in Q1 FY26 and 24.8% in Q4 FY26)
  • PAT: ₹26.62 crore (119% YoY growth from ₹11.93 crore in Q1 FY26)
  • PAT Margin: 16% (up from 11% in Q1 FY26)

Standalone Results (Q1 FY27)

  • Revenue from operations: ₹162.35 crore
  • Total Revenue: ₹162.97 crore
  • Profit before tax: ₹33.99 crore
  • Profit after tax: ₹25.63 crore
  • Basic EPS: ₹24.70 (non-annualized)

Comparative Performance

Q1 FY27 vs Q1 FY26: Revenue grew 46% YoY, PAT surged 119% YoY

Q1 FY27 vs Q4 FY26: Revenue grew 3% QoQ, PAT grew 3% QoQ

Management Guidance Update

Management raised FY27 guidance across all key metrics:

  • Revenue: ₹700+ crore (39%+ YoY growth)
  • EBITDA: ₹189-196+ crore (27-28%+ margin)
  • PAT: ₹109+ crore (15.5%+ margin)

Operational Highlights

  • Completed 13 Bioequivalence (BE) studies: 7 from General unit, 2 from Beta Lactam, and 4 from Oncology
  • Part of 40 molecule BE program including 3 injectables and 37 OSDs
  • Filings for completed BE studies made in 15+ countries
  • Secured 15+ new product registrations across Malaysia, Algeria, Peru, and Mexico
  • Received approval to initiate pre-clinical batches for Pembrolizumab (second biologics candidate)
  • Erythropoietin has progressed to clinical trial stage
  • Hormone manufacturing facility construction on schedule, completion anticipated by November 2026

Manufacturing and Regulatory

  • Operates five state-of-the-art manufacturing facilities
  • Accredited by premier global regulators: PIC/S (including ANVISA and SFDA), INVIMA, DIGEMID, and EU-GMP
  • Presence in over 70+ countries

Board Meeting Details

  • Meeting held on August 10, 2026
  • Commenced at 10:30 a.m. and concluded at 11:55 a.m.
  • Audit Committee reviewed financial results on August 10, 2026

Auditor Review

  • Statutory auditors Vijay Mehra & Co. carried out limited review of results
  • Issued unmodified review reports for both standalone and consolidated financial results
  • Review conducted in accordance with Standard on Review Engagements (SRE) 2410

Subsidiary Information

  • Kwality Pharmaceuticals Africa Limitada (foreign subsidiary)
  • Subsidiary revenue: ₹0.00 lakhs for quarter ended June 30, 2026
  • Subsidiary PAT: ₹-0.45 lakhs for quarter ended June 30, 2026
  • Considered not material to the Group

Capital Structure

  • Paid-up Equity Share Capital: ₹10.38 crore (Face value ₹10 each)
  • No change in share capital during the quarter

Accounting Standards and Compliance

  • Financial results prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting"
  • Single reportable segment (Pharmaceuticals) as per Accounting Standard 17
  • EPS calculated as per Accounting Standard on Earning Per Share (AS 20)
  • Previous period figures regrouped/rearranged for correspondence

Additional Information

  • Figures for quarter ended March 31, 2026 are balancing figures between audited full year and unaudited published year-to-date figures